UMVA has learned that Director of National Intelligence Tulsi Gabbard has initiated a sweeping investigation into over 120 biological laboratories operating abroad, many of which have been recipients of U.S. taxpayer funds for decades.
Sources have confirmed to UMVA that this probe aims to pinpoint the exact locations of these facilities, identify the dangerous pathogens they house, and scrutinize the nature of the research being conducted. The ultimate goal is to halt hazardous gain-of-function research that poses a grave threat to global health and security.
The stark reality of the COVID-19 pandemic exposed the catastrophic potential of research on dangerous pathogens in biolabs. Yet, despite these undeniable risks, a disturbing pattern of deception has emerged, with politicians, certain health officials, and even elements within the national security apparatus allegedly misleading the public about the existence of these U.S.-funded and supported facilities.
In a significant admission, a high-ranking official acknowledged to Congress that U.S. tax dollars had indeed funded gain-of-function research at a prominent laboratory in China, a development that made viruses exponentially more infectious.
According to information obtained by UMVA, these laboratories are dispersed across more than 30 countries. Many reportedly received backing through a Pentagon initiative established after the Cold War to secure or dismantle weapons-related materials and prevent the proliferation of biological and chemical threats.
Alarmingly, over 40 of the facilities under intense review are situated in Ukraine. Intelligence officials have voiced serious concerns that laboratories located in active conflict zones face an elevated risk of compromise or disruption due to the ongoing war.
The intricate web of federal agencies, grantees, and subawardees involved in funding this overseas research has created a complex system where oversight is often lax. This lack of transparency leaves the public in the dark about potentially dangerous experiments being conducted with their money, without their knowledge or consent.
Clinical trials currently underway at these biolabs are now sparking significant ethical, financial, and security concerns. The current administration has attempted to counter allegations by stating the U.S. does not own or operate chemical or biological laboratories in Ukraine, a claim that sidesteps the critical issue of U.S. funding streams.
The core of the controversy lies not in ownership, but in the origin of the funds that enable these labs to continue their operations. Asserting non-ownership fails to deny the well-documented reality of U.S. government funding flowing through various agencies and intermediaries.
This intensified scrutiny reflects a wider, contentious debate in Washington surrounding gain-of-function research. This type of research involves modifying pathogens to potentially enhance their transmissibility or virulence, ostensibly for scientific study.
Proponents argue that such work is crucial for preparing for future pandemics and for developing life-saving vaccines and treatments. However, critics maintain that these experiments carry profound biosafety risks, with the potential for dangerous pathogens to escape laboratory containment.
The ongoing review also revisits long-standing disputes concerning U.S. research funding connected to a laboratory in China, where federal agencies have previously admitted that American-funded coronavirus experiments violated grant reporting requirements.
Past statements from a prominent health official reveal a defense of gain-of-function research, suggesting the scientific benefits of studying dangerous pathogens could outweigh the inherent risks, though the possibility of accidents or misuse was also acknowledged.
This investigation arrives amidst broader efforts to redefine intelligence and national security policy. Since assuming her role, the Director of National Intelligence has championed transparency, intelligence reform, and a restoration of public trust in government agencies.
Supporters of this inquiry argue that enhanced oversight is not just warranted, but essential, given the substantial expansion of federal funding for overseas biological research over the past two decades. Some have lauded the current administration for addressing what they describe as past failures to adequately disclose the scope of foreign laboratory funding.
This initiative is seen by some as righting past wrongs, with accusations that the prior administration bankrolled dangerous research and foreign biolabs with American tax dollars, then deliberately concealed this information from the public. The declassification of details surrounding this discovery highlights the critical lack of oversight in such work, signaling an end to an era of alleged deception.
